NCT00074048已完成2 期
Phase II Trial Of BL22 Immunotoxin In Hairy Cell Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Response rate
研究概览
简要总结
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for hairy cell leukemia that has not responded to treatment with cladribine.
PURPOSE: This phase II trial is studying BL22 immunotoxin to see how well it works in treating patients previously treated with cladribine for hairy cell leukemia.
详细描述
OBJECTIVES:
Primary
- Determine the response rate in patients with cladribine-resistant hairy cell leukemia treated with BL22 immunotoxin.
Secondary
- Determine the response duration in patients treated with this drug.
- Determine the safety of this drug in these patients.
- Determine the pharmacokinetics of this drug in these patients.
- Correlate BL22 blood levels and toxicity of this drug with the development of neutralizing antibodies in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
BL22 immunotoxin
干预措施: BL22 (Drug)
结局指标
主要结局
Response rate
时间窗: After even cycle numbers (2,4,6,8,10)
次要结局
- Duration of Response: [Timeframe: Date that a response begins with the date that PD is documented.](30 days after last dose of study drug)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Immunotoxin Therapy in Treating Patients With Hairy Cell LeukemiaLeukemiaNCT00021983National Cancer Institute (NCI)
撤回
1 期
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaLymphomaLeukemiaNCT00024115National Cancer Institute (NCI)
已完成
1 期
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaLymphomaLeukemiaNCT00126646MedImmune LLC24
暂停
1 期
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's LymphomaLymphomaLeukemiaNCT00077493MedImmune LLC95
已完成
2 期
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By SurgeryMelanoma (Skin)Non-melanomatous Skin CancerNCT00295958National Institutes of Health Clinical Center (CC)26